Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Associate Professor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director, Adult Leukemia Program
Department of Medical Oncology
Division of Hematologic Malignancies
Dana-Farber Cancer Institute
Professor of Internal Medicine and Dermatology
Deputy Chair, Department of Dermatology
The University of Texas MD Anderson Cancer Center
Department of Haematology
University College London
University College London Hospital
London, United Kingdom
Editorial Director, Hematology/Oncology
Senior Managing Editor
This program is intended for physicians and other healthcare providers involved in caring for patients with hematologic malignancies.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 16, 2018, through February 15, 2019:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.
Results from KEYNOTE-042 trial of first-line pembrolizumab vs standard chemotherapy in advanced NSCLC with PD-L1 TPS ≥ 1% from ASCO 2018 reported by Clinical Care Options (CCO).
KEYNOTE-407 data on adding pembrolizumab to platinum-based chemotherapy in patients with untreated metastatic squamous NSCLC from ASCO 2018 reported by Clinical Care Options (CCO).
Downloadable PDF reviewing mutation types, FDA-approved agents, and companion diagnostics for EGFR mutations in NSCLC.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.